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Abstract
Purpose. Disease-specific survival (DSS) for proximal bile duct cancer has been reported to be worse than for carcinoma of
the distal duct. Methods. Review of two prospectively maintained databases identified 204 patients who underwent resection
for extrahepatic cholangiocarcinoma (proximal: n106, 52%; distal: n98, 48%) between December 1987 and December
2005. Patient, tumor, and treatment-related variables were reviewed. Analyses were performed to compare tumor
presentation, treatment, and DSS between patients with resected proximal and distal lesions. Results. Median follow-up for
the 204 resected patients was 24 months (range 1165 months) and 56 months for those alive at last follow-up. Combined
liver/bile duct resection was performed in 82% of patients with proximal lesions, and pancreaticoduodenectomy was
performed in 92% of patients with distal lesions. Patients experienced similar postoperative length of stay (median:
proximal, 13 days vs. distal, 13 days; p0.64) and operative mortality (30-day: proximal, 4% vs. distal, 3%; p1.0,
Fishers). Margin positive rates were similar (proximal, 23% vs. distal, 15%; p0.20). Estimated five-year DSS for all
patients was 35%. Tumor location (proximal vs. distal) was not associated with five-year estimated DSS (proximal, 29% vs.
distal, 43%; p0.44). Factors associated with five-year DSS included stage at presentation (node negative, 42% vs. node
positive, 22%; pB0.001), differentiation (papillary, 53% vs. non-papillary, 27%; p0.01), and margin status (margin
negative 42% vs. margin positive 27%; pB0.001). Conclusions. These results suggest that patients with resected proximal
and distal cholangiocarcinoma will experience similar operative outcomes and DSS.
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Introduction
Primary bile duct cancer is an uncommon cancer in
the USA (incidence: 12/100,000/year) and may arise
anywhere within the biliary tree. Tumors involving the
extrahepatic ducts have been considered to be more
common than intrahepatic lesions, and reports of
selected patients suggest that lesions of the proximal
extrahepatic ducts are more common than lesions of
the distal duct [1]. The division of extrahepatic
cholangiocarcinoma into proximal (hilar), distal, and
sometimes mid-duct categories has been based pri-
marily on differences in approach to biliary drainage,
diagnosis, and operative resection rather than to any
identified difference in tumor biology [24].
Because of differences in approach and manage-
ment there are currently only a few large studies
directly comparing outcome between proximal and
distal cholangiocarcinoma [37]. These studies have
in general reported improved survival in patients with
distal lesions. The interpretation of these studies is
complicated by the fact that many include patients
who did not undergo resection, and are from an era
when operative mortality was significantly higher for
proximal lesions. Tompkins et al. published a review
in 1981 of 96 patients with extrahepatic cholangio-
carcinoma and the median survival was nine months,
10 months, and 21 months for proximal, mid, and
distal lesions, respectively [4]. All patients treated at
their institution between 1954 and 1978 were in-
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cluded. Fewer than half of the patients (47%) with
proximal lesions underwent resection and the opera-
tive mortality rate was 23%. Resection was performed
in 67% of patients with distal lesions, and the
operative mortality in this group was 8%.
The goal of the current study was to evaluate and
compare the operative results and long-term disease-
specific outcome of patients resected for extrahepatic
bile duct cancer at a single institution. Comparisons
between proximal and distal lesions were limited to
only those patients who underwent resection in an
effort to compare outcome in a group of patients with
similar stage disease.
Methods
Over an 18-year period from December 1987 to
December 2005, 204 patients underwent resection
for extrahepatic bile duct carcinoma at Memorial
Sloan-Kettering Cancer Center (MSKCC). All pa-
tients were identified from one of two prospectively
maintained operative databases (liver database, pan-
creatic database) that contain demographic, clinical,
operative, pathologic, and follow-up data. Permission
for studying these patients was obtained from the
MSKCC Institutional Review and Privacy Board
according to institutional policy for protected health
information.
Patients were included if they underwent resection
of an extrahepatic bile duct carcinoma (cholangiocar-
cinoma). Patients who were explored but did not
undergo resection were excluded. Patients with gall-
bladder carcinoma were not included. Proximal
tumors were defined as those lesions involving the
biliary confluence or from the extrahepatic right or left
hepatic ducts and typically requiring hepatic resec-
tion. Distal tumors were defined as those arising from
the distal duct, generally distal to the insertion of the
cystic duct, and typically requiring pancreatic resec-
tion. Patients with intrahepatic cholangiocarcinoma
secondarily involving the extrahepatic ducts were
excluded. In patients who did not undergo liver
resection (proximal tumors) or pancreatic resection
(distal tumors) the classification of proximal or distal
was based on the relationship to the cystic duct. In
many reports these lesions would be classified as mid-
duct tumors, however in an effort to avoid selective
exclusion, these were classified as proximal if arising
proximal to the cystic duct insertion.
Patient, tumor, and treatment-related variables
were retrieved from the database and confirmed by
chart review. Patient variables included age, gender,
and selected preoperative laboratory values. Treat-
ment-related variables included the nature of the
resection (liver and bile duct resection, bile duct
resection, pancreatectomy), operative blood loss,
and postoperative length of stay. Patients were con-
sidered to have died from postoperative complications
if death occurred within 30 days of operation. Patients
were categorized at the time of last follow-up into the
following categories: no evidence of disease (NED),
alive with disease (AWD), dead of disease (DOD),
postoperative death (POD), and dead of other causes
(DOC). The length of follow-up was calculated as the
time between the date of operation and the date of last
follow-up or death. Death of disease was considered
an event in the disease-specific survival (DSS) analy-
sis.
Final pathology reports were reviewed retrospec-
tively to confirm the presence of extrahepatic cholan-
giocarcinoma. All tumors were staged according to
the 6th edition of the American Joint Committee on
Cancer Staging Handbook [8]. Primary tumor size
was recorded as the largest diameter axis through the
sectioned specimen. Histologic differentiation was
categorized into two groups for analysis: well-differ-
entiated and not well-differentiated (poor and mod-
erate). All lesions were reviewed for the presence of
papillary components. The previously published
methodology for the classification of the papillary
sub-type was utilized [9]. The absence of microscopic
disease involving any resection margin was considered
a margin-negative (R0) resection. The total number
of examined lymph nodes and the number of histo-
logically positive metastatic lymph nodes within each
surgical specimen were recorded.
Analyses were performed to compare tumor pre-
sentation, treatment, and DSS between patients with
resected proximal and distal cholangiocarcinoma.
Continuous variables were dichotomized at their
median values. Differences between proximal and
distal groups were tested using chi-square tests for
categorical variables and Wilcoxon tests for contin-
uous variables, with the exception of operative mor-
tality where Fisher’s exact test was used to account for
a small number of events. Univariate Cox propor-
tional hazards regression was used to identify factors
individually predictive of DSS. Stepwise multivariate
Cox proportional hazards regression was used to
identify factors multivariately predictive of DSS.
Entry and exit criteria in the stepwise model were
set at an alpha level of 0.10. P-values from the
univariate and multivariate Cox models were from
the Wald test. All tests were two-sided and statistical
significance was achieved at pB0.05. Statistical ana-
lysis was performed with SAS statistical software
version 9.1 (SAS institute Inc, Cary, NC).
Results
Over the 18-year time period 204 patients underwent
resection for extrahepatic bile duct carcinoma.
Roughly half of these lesions were proximal tumors
(n106, 52%). The patient, tumor, and treatment-
related variables for these 204 patients are presented
in Table I. Resection required combined liver and bile
duct resection for 87 of the 106 tumors classified as
proximal lesions (82%), and pancreatic resection was
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performed in 90 of the 98 tumors classified as distal
(90/98, 92%). Bile duct resection with portal node
dissection alone was performed in 27 patients and in
19 of these cases the lesions were categorized as
proximal. The majority of tumors were pathologically
classified as T3 (n131, 66%) and metastatic spread
to regional lymph nodes was identified in 34% of
patients. The median postoperative length of stay was
13 days and the operative mortality (30-day mortality)
was 4% for proximal lesions and 3% for distal lesions
(p1.0, Fishers exact).
A comparison between patient, tumor, and treat-
ment-related variables in patients with proximal and
distal cholangiocarcinoma is presented in Table II.
Patients with distal lesions had a greater number of
regional nodes pathologically assessed (median: distal,
12 vs. proximal, 3; pB0.001), and were more likely to
be node positive (47% vs. 21%, pB0.001). Distal
lesions were more likely to have a more advanced
AJCC stage (see Table II). No patient with a distal
lesion underwent resection and was found to have an
in situ or T1, N0 tumor. Patients who underwent
resection for proximal cholangiocarcinoma were more
likely to present with tumors described as well-
differentiated and/or papillary in nature. Lesions of
the proximal duct were noted to be larger in size
(median: proximal, 2.4 cm vs. distal, 2.0 cm; p
0.05).
The median follow-up for the 204 resected patients
was 24 months (range 1165 months) and 56 months
for those alive at the time of last follow-up. The
estimated five-year DSS for the 204 patients in the
study was 35% (Figure 1). The univariate Cox model
results between patient, tumor, and treatment-related
variables and DSS is presented in Table III. The
location of the lesion was not associated with esti-
mated five-year DSS (proximal, 29% vs. distal, 43%;
p0.44, Figure 2). Factors associated with five-year
DSS included stage at presentation (node negative,
42% vs. node positive, 22%; pB0.001), tumor
differentiation (papillary, 53% vs. non-papillary, 27%;
p0.01), and the presence of a positive margin
(margin negative 42% vs. margin positive 10%; pB
0.001). Multivariate analysis identified a negative
margin (hazard ratio, 3.68; 95% confidence interval,
2.385.69) and well-differentiation (hazard ratio,
0.42; 95% confidence interval, 0.260.67) to be
predictors of improved survival.
AJCC stage at presentation was associated with
DSS for the 204 resected patients. Patients with stage
1B (T2, N0, M0) lesions, however, experienced
similar estimated five-year DSS as patients resected
with stage 2A lesions (T3, N0, M0). This similarity in
DSS between T2 and T3 tumors appeared to be
secondary to overlap in the survival of patients with
proximal lesions. Within the proximal group the
estimated five-year DSS for T2 lesions was lower
21%, although not statistically lower, than five-year
DSS for T3 lesions (33%, p0.23, Figure 3). For
patients with distal lesions, the DSS estimates for T2
and T3 tumors (within the node negative group)
stratified as would be expected (Figure 4). The five-
year DSS for patients with distal lesions who under-
went resection for a T2 lesion was 62%, and 40% for
those resected for T3 lesions (p0.08).
Discussion
In the current study 204 patients underwent resection
for extrahepatic bile duct cancer over an 18-year time
period. Proximal tumors were present in 52% of
patients and distal tumors were present in 48% of
patients. Patient and operative outcomes were similar
between patients with proximal and distal lesions. In
both groups the median age was similar (65 years
proximal vs. 67 years distal), postoperative length of
stay was 13 days, estimated blood loss was similar
(median 800 cm3, both groups) and postoperative
mortality was similar (30-day mortality: proximal, 4%
vs. distal, 3%; pNS). Estimated five-year DSS was
35% for the 206 resected patients and did not differ
between those with proximal and distal tumors (five-
year DSS: proximal, 29% vs. distal, 43%; p0.44).
Previous studies have suggested that patients who
present with proximal bile duct cancer have worse
disease-specific outcomes than those with distal
lesions [4,6]. In one of the largest single institution
studies of proximal and distal bile duct cancer from
Johns Hopkins Medical Center 294 patients with
cholangiocarcinoma (intrahepatic in 18 patients)
were presented [6]. In this study the five-year survival
was 11% for patients with proximal tumors and 28%
for patients with distal lesions. Similarly, in a report by
Tompkins et al. of 96 patients with extrahepatic
cholangiocarcinoma the median survival was nine
Table I. Patient, tumor, and treatment-related variables for 204
patients resected for extrahepatic cholangiocarcinoma.
Factor No. of patients %
Gender (male) 122 60
Tumor location
Proximal bile duct 106 52
Distal bile duct 98 48
Operation
Liver and bile duct resection 87 43
Pancreatectomy 90 44
Bile duct resection 27 13
Resection margin positive 39 19
T-stage (n194)
T1 7 4
T2 56 28
T3 131 66
Node positive 68 33
Postoperative death 7 3
Median Range
Age at diagnosis (years) 68 3487
Postoperative length of stay (days) 13 682
Length of follow-up (months) 24 1165
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Table II. Comparison of patient, tumor, and treatment-related variables for patients undergoing resection for proximal and distal
extrahepatic cholangiocarcinoma (n204).
Variable Proximal (n106) n (%) Distal (n98) n (%) P-value*
Gender
Male 58 (55%) 64 (65%) 0.12
Age
Years (mean) 65 67 0.22
Stage
0 (Tis) 5 (5) 0 (0) B0.0001
1A 8 (8) 1 (1)
1B 29 (27) 15 (16)
2A 42 (40) 32 (34)
2B 22 (21) 47 (49)
Nodal status
Node negative 84 (79) 51 (53) B0.0001
Node positive 22 (21) 46 (47)
Margins
Negative margins 82 (77) 82 (85) 0.20
Positive margins 24 (23) 15 (15)
Differentiation
Not well-differentiated 68 (66) 74 (86) 0.002
Well-differentiated 35 (34) 12 (14)
Papillary
Yes 25 (24) 9 (3) B0.001
No 81 (76) 95 (97)
Size
Median, cm (range) 2.4 (0.410.7) 2.0 (0.28.4) 0.05
Number nodes assessed
Median (range) 3 (011) 12 (242) B0.001
Length of stay
Median, days (range) 13 (649) 13 (682) 0.64
Estimated blood loss
Median, CC (range) 800 (1307000) 800 (1007500) 0.23
Postoperative deaths 4 (3.8) 3 (3.1) 1.0
*P-values for categorical variables calculated from x2 test.
Note: P-values for continuous variables are from Wilcoxon test with exception of p-value for postoperative deaths which was calculated from
Fishers Exact test.
P-valuesB0.05 highlighted in bold.
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Figure 1. Disease-specific survival (DSS) in 204 patients resected
for extrahepatic cholangiocarcinoma.
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Figure 2. Comparison of estimated disease-specific survival (DSS)
between patients resected for proximal and distal cholangiocarci-
noma.
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months, 10 months, and 21 months for proximal,
mid, and distal lesions, respectively [4]. The conclu-
sion from this latter study was that the location of the
lesion within the bile duct appeared to bear the most
important relationship to prognosis.
The prognostic significance of location within the
duct appears to be most associated with the ability to
resect the lesion, obtain a negative margin, and with
the risk of postoperative mortality rather than with a
primary difference in tumor biology. In the study
from Johns Hopkins noted above the resection rate
for patients with proximal tumors was 56% com-
pared to 91% in patients with distal lesions. The
operative mortality rate was higher in patients
resected for proximal lesions (3.6% for proximal
lesions and 1.3% for distal lesions) and the margin
positive rate was 74% in proximal lesions compared
to 10% for distal lesions. These studies, which
include both resected and unresected patients, de-
monstrate a better outcome for distal lesions but
suggest that this is secondary to a decreased ability to
resect proximal lesions because of later stage at
diagnosis and the technical challenges of proximal
resection.
Reports that have limited comparison to only
patients who have undergone resection have found
similar results as our study [3,5,10]. Nagorney et al.
reported on 171 patients with extrahepatic cholangio-
carcinoma and found similar survival amongst re-
sected patients with proximal and distal lesions [3].
Hernandez et al. reported on 91 patients resected for
extrahepatic cholangiocarcinoma at the University of
South Florida [10]. Operative mortality was similar
(postoperative mortality: proximal, 15% vs. distal,
9%; p0.36) and median survival was similar (med-
ian survival: proximal, 22 months vs. distal, 17
months; pNS).
Factors identified in the current study as predictive
of decreased DSS included metastatic disease to
regional nodes, poorly differentiated tumors, and
positive surgical margins. The latter factor was similar
between proximal and distal groups; however, patients
with distal lesions were statistically more likely to have
positive nodes identified and less likely to have well-
differentiated tumors. The majority of well-differen-
tiated lesions in the proximal duct had a papillary
component. Papillary lesions in the distal dust were
extremely uncommon. Protein expression profiles
suggest differences between papillary and non-papil-
lary tumors which are associated with improved
prognosis and do suggest a possible biologic differ-
ence between papillary and non-papillary cholangio-
carcinoma [11].
In the current study, the differences between
proximal and distal lesions with respect to tumor
Table III. Univariate Cox proportional hazards results for disease-specific survival (excludes operative deaths).
Variable Hazard ratio* and 95% CI P-value**
Proximal vs. Distal 1.16 (0.801.69) 0.44
Node positive vs. Node negative 2.19 (1.503.21) B0.0001
Positive margins vs. Negative margins 3.18 (2.094.83) B0.0001
Well-differentiated vs. not Well-differentiated 0.46 (0.290.74) 0.001
Size (continuous) 0.97 (0.851.11) 0.65
Size ]2.5 vs. Size B2.5 0.85 (0.561.30) 0.45
Length of stay (continuous) 0.99 (0.971.02) 0.60
Length of stay ]13 days vs. Length of stay B13 days 1.00 (0.691.46) 0.99
Estimated blood loss in 100 cm3 (continuous) 1.00 (0.981.02) 0.96
Estimate blood loss ]800 cm3 vs. Estimated blood loss B800 cm3 0.98 (0.661.44) 0.90
*Hazard ratio determined from univariate Cox proportional hazards model.
**P-value from Wald test.
P-valuesB0.05 highlighted in bold.
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Figure 3. Stage-specific disease-specific survival for patients re-
sected for extrahepatic cholangiocarcinoma.
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Figure 4. Stage-specific disease-specific survival for patients re-
sected for proximal extrahepatic cholangiocarcinoma.
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differentiation and regional nodal spread did not
result in any identifiable difference in survival. It is
possible that the observed difference in the rate of
regional nodal spread may represent a difference in
nodal resection and pathologic assessment. Patients
with resected distal lesions had a median of 12 nodes
assessed and patients with proximal lesions had a
median of two nodes assessed (pB0.001). This
difference is almost certainly due the anatomic
limitations of portal node dissection for proximal
tumors and highlights the importance of both opera-
tive dissection and pathologic assessment for accurate
staging. As nodal status is a strong predictor of
survival many groups have recommended a more
extensive nodal dissection for proximal tumors
[12,13]. This dissection may result in more precise
staging, however, a therapeutic effect has never been
demonstrated, and thus the potential morbidity of
extended lymphadenectomy should be considered.
The current AJCC staging system (6th edition) for
bile duct cancer utilizes a similar classification system
as for pancreatic adenocarcinoma. The current study,
as well as others, has identified limitations of this
system within the tumor (T) staging category. In the
current study the survival for patients with T2 and T3
lesions overlapped for the entire group and this lack of
stratification appeared to be secondary to the prox-
imal group alone. T2 lesions are defined as invading
beyond the wall of the bile duct, and T3 lesions are
defined as invading another organ or blood vessel. It is
possible that this system is more applicable to distal
lesions because this segment of the bile duct is within
the head of the pancreas. Thus, as lesions grow in the
distal duct they invade into the pancreas in a
consistent fashion. The proximal duct is not em-
bedded within any organ and therefore invasion into
the liver or portal vein may not be consistent, and very
dependent on the exact location. This finding has also
been reported by others, and should encourage the
evaluation of other approaches to primary tumor
prognostic stratification [5].
In conclusion, the results from the current study
suggest that patients undergoing resection for extra-
hepatic bile duct cancer will experience similar short-
term and long-term survival regardless of location. In
this study the histologic factors of tumor differentia-
tion, the stage-related factors such as regional nodal
spread, and the ability to obtain a negative margin
were predictive of DSS. Operative resection is
warranted in patients who present with radiographi-
cally resectable extrahepatic cholangiocarcinoma re-
gardless of location within the bile duct.
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